Not yet recruitingPhase 1

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes.

Lead sponsor

Eli Lilly and Company

Assets

Eloralintide / Macupatide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07765511

Org study ID27505

Secondary IDJ2V-JE-GZLEEli Lilly and Company

Timeline

Milestones

Study first posted2026-08-14actual

Last update posted2026-08-14actual

Study start2026-10estimated (month precision)

Primary completion2027-06estimated (month precision)

Study completion2027-06estimated (month precision)

Assets

Investigational agents

Eloralintide Macupatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are Japanese participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who agree to contraception requirements or participants who are individuals not of childbearing potential (INOCBP).

•Have a body mass index greater than or equal to (≥)25 kilograms per square meter (kg/m²)

•Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5 percent (%) body weight change.

Exclusion criteria

•Have known allergies to related compounds of macupatide or eloralintide, or any components of the formulations.

•Have a history of significant atopy, including severe allergic manifestations, or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions.

•Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders, within the last 3 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.

•Have been diagnosed with Type 1 or Type 2 diabetes mellitus.

•Have a history of chronic medical conditions involving the heart, liver, or kidneys.

•Have a history of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.

•Have a history or presence of a gastrointestinal (GI) disorder or previous surgery that impacts gastric emptying.

•Have had or plan to have during the study, a device-based or surgical treatment use for obesity.

•Have been treated, or plan to be treated, with prescription medications or other non approved drugs intended to promote weight loss, within 3 months prior to screening.

•Are currently enrolled or have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.

•Have previously completed or withdrawn from this study or have previously received macupatide or eloralintide.

•Have evidence of acute or chronic liver disease or pancreatic disease.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Percent Change in Body Weight

Time frame:Baseline through Week 25

percent change from baseline, improvement

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:End of Study (Week 25)

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Macupatide

Time frame:Baseline through Week 25

concentration, descriptive

Secondary/protocol endpoint

PK: AUC of Macupatide in Combination with Eloralintide

Time frame:Baseline through Week 25

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Concentration (Cmax) of Macupatide

Time frame:Baseline through Week 25

concentration, descriptive

Secondary/protocol endpoint

PK: Cmax of Macupatide in Combination with Eloralintide

Time frame:Baseline through Week 25

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.